Published in
Springer, Investigational New Drugs, 5(34), p. 614-624, 2016
DOI: 10.1007/s10637-016-0375-2
Links
Tools
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia
Journal article published in 2016 by
Karen W. L. Yee,
Hsiao-Wei T. Chen,
David W. Hedley,
Sue Chow,
Joseph Brandwein,
Andre C. Schuh,
Aaron D. Schimmer,
Vikas Gupta 
,
Deborah Sanfelice,
Tara Johnson,
Lisa W. Le,
Jamie Arnott,
Mark R. Bray,
Carolyn Sidor,
Mark D. Minden
,
Deborah Sanfelice,
Tara Johnson,
Lisa W. Le,
Jamie Arnott,
Mark R. Bray,
Carolyn Sidor,
Mark D. Minden
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 